Canada markets close in 3 hours 47 minutes

ProMIS Neurosciences, Inc. (PMN.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
7.70+0.10 (+1.32%)
As of 11:30AM EDT. Market open.

ProMIS Neurosciences, Inc.

1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2
Canada

https://www.promisneurosciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees5

Key Executives

NameTitlePayExercisedYear Born
Mr. Eugene WilliamsChairman & CEO489.38kN/A1959
Dr. Neil R. Cashman M.D.Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director99kN/A1952
Mr. Daniel E. Geffken M.B.A., MBAChief Financial Officer122.28kN/A1957
Mr. Gavin T. MalenfantChief Operating Officer53.32kN/A1962
Dr. Johanne Kaplan Ph.D.Chief Devel. Officer357.49kN/AN/A
Dr. Ernest D. Bush Ph.D.Head of Pharmacology/Toxicology & Sr. ConsultantN/AN/AN/A
Dr. David Wishart Ph.D.Chief Physics OfficerN/AN/AN/A
Mr. Dennis Chen Ph.D.Head of Manufacturing & Sr. ConsultantN/AN/AN/A
Dr. Larry Douglas Altstiel M.D., Ph.D.Chief Medical OfficerN/AN/A1950
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Corporate Governance

ProMIS Neurosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.